Table 3. Epidemiologic and economic burden (median (95% credibility range), costs in millions ($US)) of CRE infections in the United States assuming a 26% attributable mortality and meropenem use for carbapenem therapies.

	CRE incidence per 100 000
	2.93	6	10	15
Infections	9418	19 285	32 142	48 213
Deaths	840	1721	2868	4301
QALYs lost	8841 (5805–12 420)	18 105 (11 888–25 433)	30 174 (19 814–42 388)	45 261 (29 720–63 581)
Hospital perspective	275 (217–334)	562 (443–685)	937 (739–1141)	1406 (1109–1712)
Third-party payer perspective	147 (129–172)	302 (264–353)	503 (440–588)	754 (661–882)
Productivity losses because of absenteeism	11 (5–46)	22 (9–94)	37 (16–157)	56 (24–236)
Productivity losses because of death	389 (149–1407)	796 (306–2882)	1327 (509–4803)	1990 (764–7205)
Societal perspective	553 (303–1593)	1132 (620–3262)	1886 (1034–5437)	2830 (1550–8155)